Yunzheng Li
Overview
Explore the profile of Yunzheng Li including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
92
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang L, Mai X, Li B, Li H, Liu Q, Li Y, et al.
Eur Radiol
. 2024 Nov;
PMID: 39576331
Objectives: This study explored the clinical prognosis and lipidomics of hepatitis B virus steatohepatitic hepatocellular carcinoma (HBV-SHHCC) and aimed to identify a noninvasive and convenient method to diagnose this phenotype...
2.
Xu T, Yu L, Cao Y, Li B, Li Y, Zhang L, et al.
Transl Res
. 2024 Nov;
275:18-31.
PMID: 39528003
Hepatocellular carcinoma (HCC) is a prevalent malignant tumor requiring effective treatments. Oncolytic viruses induce anti-tumor responses but have limited efficacy. Apolipoprotein A1 (ApoA1) inhibits inflammation, modulates immunity, and promotes anti-oxidation....
3.
Bao G, Wei H, Yan J, Li Y, Xue C, Fu R, et al.
J Cancer Res Clin Oncol
. 2024 Sep;
150(9):422.
PMID: 39292289
Purpose: This research aimed to evaluate the expression level of Homeobox A9 (HOXA9) and its role in tumorigenesis of hepatocellular carcinoma (HCC). Methods: Bioinformatic analysis, qPCR and Western blot analysis...
4.
Li B, Yang Y, Shi J, Li Y, Xu Y, Zhu Y, et al.
Hepatology
. 2024 Aug;
80(4):E58-E59.
PMID: 39101818
No abstract available.
5.
Wang Y, Cheng C, Lu Y, Lian Z, Liu Q, Xu Y, et al.
Cancer Res
. 2024 Feb;
84(10):1643-1658.
PMID: 38417136
Significance: Ammonia metabolism reprogramming mediated by aberrant activation of β-catenin induces resistance to senescence in HCC and can be targeted by inhibiting SLC4A11 as a potential therapy for β-catenin mutant...
6.
Geng L, Zhu M, Luo D, Chen H, Li B, Lao Y, et al.
Oncogene
. 2024 Jan;
43(9):682-692.
PMID: 38216672
Hepatocellular carcinoma (HCC) stands as the fifth most prevalent malignant tumor on a global scale and presents as the second leading cause of cancer-related mortality. DNA damage-based radiotherapy (RT) plays...
7.
Xu Y, Li Y, Lu Y, Wang W, Lian Z, Wu Z, et al.
J Hepatocell Carcinoma
. 2023 Dec;
10:2197-2209.
PMID: 38090626
Background: Hepatocellular carcinoma (HCC) is one of the most serious malignant tumors threatening human life with a high mortality rate. The liver regenerative capacity after hepatectomy in early-stage HCC patients...
8.
Zhang L, Su K, Liu Q, Li B, Wang Y, Cheng C, et al.
BMC Cancer
. 2023 Nov;
23(1):1081.
PMID: 37946141
Purpose: The pathological diagnosis and prognosis prediction of hepatocellular carcinoma (HCC) is challenging due to the lack of specific biomarkers. This study aimed to validate the diagnostic and prognostic efficiency...
9.
Li B, Li Y, Zhou H, Xu Y, Cao Y, Cheng C, et al.
Hepatology
. 2023 Aug;
79(2):289-306.
PMID: 37540187
Background And Aims: Molecular classification is a promising tool for prognosis prediction and optimizing precision therapy for HCC. Here, we aimed to develop a molecular classification of HCC based on...
10.
Jiang X, Peng J, Xie Y, Xu Y, Liu Q, Cheng C, et al.
Cell Death Differ
. 2023 Jul;
30(8):1931-1942.
PMID: 37419985
Oxoglutarate dehydrogenase-like (OGDHL) is considered to be the isoenzyme of oxyglutarate dehydrogenase (OGDH) in the OGDH complex, which degrades glucose and glutamate. OGDHL was reported to reprogram glutamine metabolism to...